Component
Rho membrane translocation and GTP binding
Membrane localisation and nucleotide binding of Rho measured together.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Mevastatin inhibited Rho membrane translocation by about 60 percent and Rho GTP-binding activity by about 78 percent, both reversed by geranylgeranyl diphosphate but not by farnesyl diphosphate.
Experimental context and source evidence
- duration
- Not stated here
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- experimental_model
- Human endothelial cells
- exposure
- Mevastatin with or without geranylgeranyl diphosphate or farnesyl diphosphate
- limitations
- Measured for Rho as a group by immunoblot and GTP-gamma-S binding, not resolved to individual Rho family members.
- organism
- Human endothelial cells
- plain_language
- Mevastatin inhibited Rho membrane translocation by about 60 percent and Rho GTP-binding activity by about 78 percent, both reversed by geranylgeranyl diphosphate but not by farnesyl diphosphate.
- primary_references
- Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. (1998). https://pubmed.ncbi.nlm.nih.gov/9727051/ DOI: 10.1074/jbc.273.37.24266
- route
- In vitro
- tissue
- Rho GTPase membrane localisation and nucleotide binding
Atorvastatin: mechanism of action from target occupancy to isoprenoids, transport, muscle and metabolism (2026-09-22) · lines 78–87
Original AI-assisted curation of twelve primary studies resolved by PubMed title search and cross-checked against live PubMed metadata. Findings obtained with mevastatin, simvastatin or the statin class are recorded against those subjects. Study-specific citations, doses, negative findings and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft
## statin-inhibits-rho-membrane-translocation Mevastatin inhibited Rho membrane translocation by about 60 percent and Rho GTP-binding activity by about 78 percent, both reversed by geranylgeranyl diphosphate but not by farnesyl diphosphate. Model/species: Human endothelial cells Tissue/system: Rho GTPase membrane localisation and nucleotide binding Exposure: Mevastatin with or without geranylgeranyl diphosphate or farnesyl diphosphate Route: In vitro Duration: Not stated here Limits: Measured for Rho as a group by immunoblot and GTP-gamma-S binding, not resolved to individual Rho family members. Primary reference: Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. (1998). https://pubmed.ncbi.nlm.nih.gov/9727051/ DOI: 10.1074/jbc.273.37.24266 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.